AKT1 and gastric cancer: Inhibition of SLC2A3 by miR-129-5p suppresses glucose consumption in gastric cancer cells by regulating the PI3K-Akt and MAPK signaling pathways, suggesting that SLC2A3 is a potential therapeutic target for the treatment of gastric cancer (Chen et al., 2018).